The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Curcumin and neurodegenerative diseases: a perspective
Abstract
INTRODUCTION: Curcumin, a dietary polyphenol found in the curry spice turmeric, possesses potent antioxidant and anti-inflammatory properties and an ability to modulate multiple targets implicated in the pathogenesis of chronic illness. Curcumin has shown therapeutic potential for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). AREAS COVERED: This article highlights the background and epidemiological evidence of curcumin's health benefits and its pharmacodynamic and pharmacokinetic profile. Curcumin's ability to counteract oxidative stress and inflammation and its capacity to modulate several molecular targets is reviewed. We highlight the neuroprotective properties of curcumin including pre-clinical evidence for its pharmacological effects in experimental models of AD and PD. The bioavailability and safety of curcumin, the development of semi-synthetic curcuminoids as well as novel formulations of curcumin are addressed. EXPERT OPINION: Curcumin possesses therapeutic potential in the amelioration of a host of neurodegenerative ailments as evidenced by its antioxidant, anti-inflammatory and anti-protein aggregation effects. However, issues such as limited bioavailability and a paucity of clinical studies examining its therapeutic effectiveness in illnesses such as AD and PD currently limit its therapeutic outreach. Considerable effort will be required to adapt curcumin as a neuroprotective agent to be used in the treatment of AD, PD and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 2×
“Also proposed are liposomes, micellar formulations, biodegradable microspheres and phospholipid and cyclodextrin complexes of curcumin [39,48].”
BackgroundOxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
Aggarwal, B. B., & Sung, B. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.11.002 · Cited by 1,140
Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal
Praticò, D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.09.001 · Cited by 606
Begum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., Heath, D. D., Rock, C. L., Pruitt, M. A., Yang, F., Hudspeth, B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137455 · Cited by 604
The effect of curcumin (turmeric) on Alzheimer’s disease: An overview
Mishra, S., & Palanivelu, K. (2008) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.40220 · Cited by 599
Neuroprotective effects of curcumin
Cole, G. M., Teter, B., & Frautschy, S. A. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_8 · Cited by 516
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432
Park, S.-Y., Kim, H.-S., Cho, E.-K., Kwon, B.-Y., Phark, S., Hwang, K.-W., & Sul, D. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.05.030 · Cited by 209
Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., Ferla, B. L., Nicotra, F., Masserini, M., Antimisiaris, S. G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.06.015 · Cited by 149 · cited 2×
“A recent study by Taylor and colleagues [46] demonstrated the ability of a liposomal preparation of curcumin in suppressing b-amyloid oligomer formation.”
Background
Cited by
Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Nair, S., Bhatnagar, P., Karmakar, M., Kumari, M., Chauhan, L. K. S., Patel, D. K., et al. (2014) · ACS Nano · doi:10.1021/nn405077y · Cited by 558
Pulido-Moran, M., Moreno-Fernandez, J., Ramirez-Tortosa, C., & Ramirez-Tortosa, M. (2016) · Molecules · doi:10.3390/molecules21030264 · Cited by 543
Neuroinflammation, Neurodegeneration, and Depression
Hurley, L. L., & Tizabi, Y. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9348-1 · Cited by 259
Wang, P., Su, C., Li, R., Wang, H., Ren, Y., Sun, H., Yang, J., Sun, J., Shi, J., Tian, J., et al. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23322 · Cited by 65
Retracted
Metadata
- Authors
- Darvesh, A. S., Carroll, R. T., Bishayee, A., Novotny, N. A., Geldenhuys, W. J., & Van der Schyf, C. J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2012-06-06
- Volume
- 21
- Issue
- 8
- Pages
- 1123-1140
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2088970027
- Cited by
- 184
- References
- 14
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.